Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals, Inc., reported the acquisition of 70,000 restricted stock units on October 30, 2026, in a Form 4 filed with the SEC on November 2, 2026.

Key Highlights

  • Grant size: Rubin acquired 70,000 restricted stock units (RSUs) in a single transaction on October 30, 2026.
  • Price: The RSUs were acquired at a price of $0, according to the filing.
  • Vesting trigger: 50% of the RSUs vest upon the closing of a described merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc.
  • Remaining vesting schedule: 15% vests on the one-year anniversary of the closing, 15% on the two-year anniversary, and 20% on the three-year anniversary of the closing.
  • Post-transaction holdings: Rubin beneficially owns 70,000 derivative securities following the reported transaction, held directly.
  • Settlement: The filing states the RSUs "are settled in common stock upon vesting."

Supernus CMO Rubin Receives Merger-Linked RSU Award

According to the Form 4 filed on November 2, 2026, Jonathan Rubin, identified as SVP and Chief Medical Officer of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), acquired 70,000 RSUs on October 30, 2026. The filing lists the transaction code as "A," indicating an acquisition, with a derivative security price of $0. The RSUs are classified as derivative securities in Table II of the filing and are settled in shares of common stock upon vesting.

The filing describes a four-installment vesting structure tied directly to a merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. Specifically, 50% of the RSUs vest upon the closing of that transaction, with subsequent tranches of 15%, 15%, and 20% vesting on the one-, two-, and three-year anniversaries of the closing, respectively. The filing does not specify a date for the closing of the described merger.

The Form 4 was signed by Timothy C. Dec as attorney-in-fact for Rubin and dated November 2, 2026. The filing indicates Rubin holds his 70,000 RSUs directly, with no indirect ownership reported for this grant. No transactions were reported in Table I covering non-derivative securities.

What Was Disclosed

The filing disclosed Rubin's acquisition of 70,000 RSUs on October 30, 2026, with vesting contingent on the closing of a described Supernus-Indivior merger and subsequent anniversaries thereof. Total beneficial ownership of the derivative security following the transaction is 70,000 units.